Lansoprazole potentiates vecuronium paralysis.
The effect of lansoprazole, a newer second generation proton pump inhibitor, on vecuronium induced muscle paralysis was evaluated. Fifty adult patients comprising grade I (normal healthy patient) and grade II (patient with a mild systemic disease) as classified by the American Society of Anesthesiologists were randomly allocated into two different groups each consisting of 25 patients. Group I (control) did not receive lansoprazole and group II (study) received 30 mg lansoprazole in the night before operation. There was no statistically significant difference (p > 0.05) in the time required for complete paralysis between group I (215.7 +/- 15.19 seconds) and group II (197.5 +/- 14.13 seconds). However, the duration of paralysis was significantly different (p < 0.05) between group I (32.7 +/- 8.7 minutes) and group II (43.9 +/- 9.3 minutes). It was concluded that there is a potential for interactions and one should carefully and closely monitor the patients to prevent prolonged paralysis in patients receiving lansoprazole, as a pre-anaesthetic medication.
Ahmed
S M
SM
Department of Anaesthesiology, JN Medical College, Aligarh.
Panja
C
C
Khan
R M
RM
Bano
S
S
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D002763:Cholecystectomy; D004357:Drug Synergism; D005260:Female; D006801:Humans; D064747:Lansoprazole; D008297:Male; D019148:Neuromuscular Blockade; D003473:Neuromuscular Nondepolarizing Agents / Q000008:administration & dosage*; D009853:Omeprazole / Q000008:administration & dosage / Q000031:analogs & derivatives*; D011229:Preanesthetic Medication; D054328:Proton Pump Inhibitors; D014673:Vecuronium Bromide / Q000008:administration & dosage*
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D003473:Neuromuscular Nondepolarizing Agents; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D014673:Vecuronium Bromide; D009853:Omeprazole